Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
103.84
(
-0.57%
)
Bitcoin
70,867.00
(
1.39%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 3900

Saturday, 06/23/2007 2:12:15 AM

Saturday, June 23, 2007 2:12:15 AM

Post# of 19309
>my question/concern is whether or not transgenically-derived biosimiliars, if that is where GTC is pointed, are going to have a greater headwind than other biosimiliars<

Possible, but I see no indications that this will be the case. As more transgenically-produced drugs are approved, the novelty will wear off and these drugs will IMO increasingly be viewed as simply recombinant biologics.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now